What is he best known for?
The fields of study Tohru Mizushima is best known for:
Tohru Mizushima is conducting research in Pseudomonas aeruginosa, Antibacterial agent and Staphylococcus aureus as part of his Bacteria study.
His Antibacterial agent study frequently intersects with other fields, such as Antibiotics.
In his works, he performs multidisciplinary study on Antibiotics and Drug resistance.
In his research, Tohru Mizushima undertakes multidisciplinary study on Drug resistance and Multiple drug resistance.
While working in this field, he studies both Staphylococcus aureus and Bacteria.
Tohru Mizushima performs integrative study on Biochemistry and Immunology.
In his study, he carries out multidisciplinary Immunology and Biochemistry research.
His research combines Pseudomonas aeruginosa and Genetics.
Many of his studies involve connections with topics such as Transporter and Gene.
His most cited work include:
- NorM, a Putative Multidrug Efflux Protein, of Vibrio parahaemolyticus and Its Homolog in Escherichia coli (345 citations)
- An Autophagic Flux Probe that Releases an Internal Control (342 citations)
- Expression in Escherichia coli of a New Multidrug Efflux Pump, MexXY, from Pseudomonas aeruginosa (228 citations)
What are the main themes of his work throughout his whole career to date
His research on Biochemistry frequently links to adjacent areas such as In vitro.
Tohru Mizushima incorporates Gene and Mutant in his studies.
Tohru Mizushima undertakes multidisciplinary studies into Pharmacology and Biochemistry in his work.
In his works, he conducts interdisciplinary research on Molecular biology and Plasmid.
His work blends Plasmid and Molecular biology studies together.
Tohru Mizushima conducted interdisciplinary study in his works that combined Genetics and Bacteria.
He connects Bacteria with Genetics in his research.
He merges DNA with Escherichia coli in his study.
In his study, Tohru Mizushima carries out multidisciplinary Escherichia coli and DNA research.
Tohru Mizushima most often published in these fields:
- Biochemistry (79.60%)
- Gene (54.73%)
- Pharmacology (35.82%)
What were the highlights of his more recent work (between 2014-2020)?
- Pharmacology (82.35%)
- Internal medicine (70.59%)
- Biochemistry (58.82%)
In recent works Tohru Mizushima was focusing on the following fields of study:
His Chemotherapy research spans across into fields like Bleomycin and Cancer research.
Tohru Mizushima merges Bleomycin with Pulmonary fibrosis in his study.
His work blends Pulmonary fibrosis and Idiopathic pulmonary fibrosis studies together.
He conducts interdisciplinary study in the fields of Cancer research and Chemotherapy through his research.
In his works, he undertakes multidisciplinary study on Pharmacology and Pathology.
He brings together Pathology and Pharmacology to produce work in his papers.
He integrates Internal medicine and Endocrinology in his research.
He undertakes multidisciplinary studies into Endocrinology and Internal medicine in his work.
He integrates many fields in his works, including Biochemistry and Organic chemistry.
Between 2014 and 2020, his most popular works were:
- An Autophagic Flux Probe that Releases an Internal Control (342 citations)
- Discovery of Novel SPAK Inhibitors That Block WNK Kinase Signaling to Cation Chloride Transporters (56 citations)
- The exacerbating roles of CCAAT/enhancer-binding protein homologous protein (CHOP) in the development of bleomycin-induced pulmonary fibrosis and the preventive effects of tauroursodeoxycholic acid (TUDCA) against pulmonary fibrosis in mice (39 citations)
In his most recent research, the most cited works focused on:
In his papers, Tohru Mizushima integrates diverse fields, such as Pharmacology and Biochemistry.
He integrates Biochemistry and Pharmacology in his studies.
His Bleomycin research extends to Internal medicine, which is thematically connected.
His study deals with a combination of Bleomycin and Pulmonary fibrosis.
Tohru Mizushima connects Pulmonary fibrosis with Idiopathic pulmonary fibrosis in his study.
He combines Idiopathic pulmonary fibrosis and Lung in his research.
He conducts interdisciplinary study in the fields of Lung and ARDS through his research.
He undertakes interdisciplinary study in the fields of ARDS and Pulmonary edema through his research.
He combines Pulmonary edema and Edema in his research.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
